Effects of tES Combined With CMDT Gait Training on Cognition, Cortical Activity, Spinal Motoneuron Excitability and Motor Performance in Stroke Individuals
NCT07236216, Not applicable, Recruiting, Mahidol University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of tES Combined With CMDT Gait Training on Cognition, Cortical Activity, Spinal Motoneuron Excitability and Motor Performance in Stroke Individuals | ClinicalTrials.gov |
| NCT number | NCT07236216 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Mahidol University | ClinicalTrials.gov |
| Conditions | Hemorrhagic Stroke, Ischemic Stroke, Subacute Stroke, Chronic Stroke Patient | ClinicalTrials.gov |
| Interventions | High-definition transcranial direct current stimulation (Active), High-definition transcranial alternating stimulation (Active), High-definition transcranial electrical stimulation (sham), Cognitive-motor dual task gait training, Conventional Physical therapy | ClinicalTrials.gov |
| First posted | 2025-11-19 | ClinicalTrials.gov |
| Last updated | 2026-02-23 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Fugl-Meyer assessment (FMA) of upper and lower extremities | Baseline, 1-day post-intervention, 1-month follow-up, and 3-month follow-up | The FMA is a clinical assessment that quantified level of motor impairement and evaluate recovery in post-stroke. The FMA Includes 33 items for the upper extremity and 17 items for the lower extremity, totaling 100 points. Higher scores indicate better motor performance. | ClinicalTrials.gov |
| Secondary | Event Related Potential (ERP) | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | ERP is a non-invasive measurement tool that detects a very small voltage generated by brain activity in response to a specific event (i.e. Stroop test, N-back test). This is a signal averaging form of EEG that detects signals starting from the onset of a stimulus to evaluate brain responses over time, those occurring at 200 milliseconds (P200), or 300 milliseconds (P300) . | ClinicalTrials.gov |
| Secondary | Absolute power | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | The raw data from electroencephalographyt (EEG) in 5-min of eye-open and eye-close conditions converted to the power distribution of brain waves in different frequencies (i.e. delta, theta, and beta) usign a Fast Fourier Transformation (FFT) | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | The Montreal Cognitive Assessment (MoCA) is used to assess cognitive functioning in eight domains: Visuospatial and executive function, Naming, Attention, Language, Abstraction, Delayed recall, Orientation, Short-term memory. Participants are instructed to complete both paper-based and verbal question-answering activities, such as drawing pictures, sorting numbers, naming animals, and reviewing vocabulary. The maximum total score is 30 points, with a high score indicating a good level of cognitive. | ClinicalTrials.gov |
| Secondary | Timed up and go test | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | Participants wear regular footware and if they have normally used gait aid, it is allowed to use in the test. The test measures the time taken when the participants stand up from the chair, walk at normal pace for 3 meters, turn around, walk back for 3 meters, and then sit on a chair. | ClinicalTrials.gov |
| Secondary | Cognitive-motor interference (CMI) | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | CMI refers to a decline in performance observed when a person simultaneously performs a cognitive and motor task, compared to performing a single- or dual-task separately. Managing both tasks requires divided attention, and interference arises when these cognitive resources are insufficient to maintain performance in both domains. The CMI can be quantified by the dual-task cost (DTC). The DTC is calculated by comparing the performance difference between single-task and dual-task conditions. Participants will be asked to perform 2 walking conditions on the treadmill (Zebris Rehawalk gait analysis and gait training). The walking conditions are single-walking and cognitive-motor dual task walking (CMDT walking). For single-walking, participants will be asked to walk at their preferred speed. For CMDT walking, participants will walk and response to stimuli on the screen simultaneously. During the test, stride length, step length, cadence and accuracy of response | ClinicalTrials.gov |
| Secondary | Soleus H-reflex | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | The H-reflex is an electrophysiological measurement used to assess spinal excitability. For the soleus H-reflex , participants will be in prone position with ankle in neutral position. A bipolar electrode will be placed over the popliteal fossa, and the surface EMG electrode will be attached to the motor point of the soleus muscle (two electrodes on the lower 1/3 of the lower leg), and the lateral malleolus (ground electrode). The electrical stimulation starts at a minimal intensity, increasing until an H-reflex response is detected, continuing to supramaximal intensity to elicit an M-wave. H-reflex latency, maximum H- and M-wave responses will be recorded. The Hmax/Mmax ratio will be calculated from maximum H- and M-wave amplitude responses. | ClinicalTrials.gov |
| Secondary | Flexor carpi radialis (FCR) H-reflexe | Baseline, 1-day post-intervention, 1-month follow-up and 3-month follow-up | For the FCR H-reflex, participants will sit with their wrist in neutral, forearm mid-pronated, and their elbow flexed at 45 degrees, with slight shoulder abduction, flexion, and neutral rotation (68). Bipolar electrode will be placed medially to cubital fossa and the biceps brachii tendon. Two surface electrodes will be positioned over the FCR (1/3 of the distance from the medial epicondyle to the radial styloid), with a grounded electrode placed over radial styloid process. For the FCR H-reflex (Figure 10), participants will sit with their wrist in neutral, forearm mid-pronated, and their elbow flexed at 45 degrees, with slight shoulder abduction, flexion, and neutral rotation (68). Bipolar electrode will be placed medially to cubital fossa and the biceps brachii tendon. Two surface electrodes will be positioned over the FCR (1/3 of the distance from the medial epicondyle to the radial styloid) (69), with a grounded electrode placed over radial styloid process. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)